stockportfolio.pro
Stocks / COAG vs IRMD
COAG vs IRMD
Hemab Therapeutics Holdings, Inc. and IRADIMED CORPORATION side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Hemab Therapeutics Holdings, Inc. (COAG) | IRADIMED CORPORATION (IRMD) | |
|---|---|---|
| Market cap | $1.2B | $1.2B |
| Revenue (latest FY) | $0 | $83.81M |
| Net income (latest FY) | $-63.91M | $22.48M |
| Revenue growth (5y CAGR) | — | 21.5% |
| Net margin | — | 26.8% |
| Return on equity | 36.2% | 23.8% |
| P/E ratio | — | 52.3 |
| Dividend yield | — | 0.8% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open COAG — free Open IRMD — freeFrequently asked questions
Which is bigger, COAG or IRMD?
Hemab Therapeutics Holdings, Inc. is larger by market capitalization — $1.2B versus $1.2B.
Which grows faster, COAG or IRMD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.